Tags

Type your tag names separated by a space and hit enter

Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Curr Med Res Opin. 2012 May; 28(5):781-8.CM

Abstract

OBJECTIVE

To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of fixed-combination brimonidine 0.2%-timolol 0.5% compared with latanoprost 0.005% in patients with glaucoma or ocular hypertension.

RESEARCH DESIGN AND METHODS

This was a prospective, randomized, multicenter, investigator-masked clinical trial. After washout of any previous IOP-lowering medications, patients with IOP of 24 mmHg or higher were randomized to twice-daily fixed-combination brimonidine 0.2%-timolol 0.5% (n = 73) or once-daily latanoprost 0.005% (n = 75, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks. IOP was measured at 8 a.m. (before dosing), 10 a.m., and 3 p.m. at baseline, week 6, and week 12.

CLINICAL TRIAL REGISTRATION

The trial is registered with the identifier 00811564 at http://www.clinicaltrials.gov .

MAIN OUTCOME MEASURES

The primary efficacy endpoint was diurnal IOP (averaged over 8 a.m., 10 a.m., and 3 p.m.) at week 12. Safety measures included biomicroscopy.

RESULTS

There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline (p = 0.118). At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794). The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131). Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups.

CONCLUSIONS

Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension. Both treatments demonstrated favorable ocular tolerability. The duration of the study was 12 weeks, and additional studies will be needed to compare the efficacy and safety of fixed-combination brimonidine-timolol and latanoprost during long-term treatment.

Authors+Show Affiliations

Wills Eye Hospital, Philadelphia, PA, USA. ljk22222@aol.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22458918

Citation

Katz, L Jay, et al. "Fixed-combination Brimonidine-timolol Versus Latanoprost in Glaucoma and Ocular Hypertension: a 12-week, Randomized, Comparison Study." Current Medical Research and Opinion, vol. 28, no. 5, 2012, pp. 781-8.
Katz LJ, Rauchman SH, Cottingham AJ, et al. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Curr Med Res Opin. 2012;28(5):781-8.
Katz, L. J., Rauchman, S. H., Cottingham, A. J., Simmons, S. T., Williams, J. M., Schiffman, R. M., & Hollander, D. A. (2012). Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Current Medical Research and Opinion, 28(5), 781-8. https://doi.org/10.1185/03007995.2012.681036
Katz LJ, et al. Fixed-combination Brimonidine-timolol Versus Latanoprost in Glaucoma and Ocular Hypertension: a 12-week, Randomized, Comparison Study. Curr Med Res Opin. 2012;28(5):781-8. PubMed PMID: 22458918.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. AU - Katz,L Jay, AU - Rauchman,Steven H, AU - Cottingham,Andrew J,Jr AU - Simmons,Steven T, AU - Williams,Julia M, AU - Schiffman,Rhett M, AU - Hollander,David A, Y1 - 2012/04/25/ PY - 2012/3/31/entrez PY - 2012/3/31/pubmed PY - 2012/9/29/medline SP - 781 EP - 8 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 28 IS - 5 N2 - OBJECTIVE: To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of fixed-combination brimonidine 0.2%-timolol 0.5% compared with latanoprost 0.005% in patients with glaucoma or ocular hypertension. RESEARCH DESIGN AND METHODS: This was a prospective, randomized, multicenter, investigator-masked clinical trial. After washout of any previous IOP-lowering medications, patients with IOP of 24 mmHg or higher were randomized to twice-daily fixed-combination brimonidine 0.2%-timolol 0.5% (n = 73) or once-daily latanoprost 0.005% (n = 75, dosed in the evening, with vehicle control in the morning to maintain masking) for 12 weeks. IOP was measured at 8 a.m. (before dosing), 10 a.m., and 3 p.m. at baseline, week 6, and week 12. CLINICAL TRIAL REGISTRATION: The trial is registered with the identifier 00811564 at http://www.clinicaltrials.gov . MAIN OUTCOME MEASURES: The primary efficacy endpoint was diurnal IOP (averaged over 8 a.m., 10 a.m., and 3 p.m.) at week 12. Safety measures included biomicroscopy. RESULTS: There was no statistically significant difference between the treatment groups in mean diurnal IOP at baseline (p = 0.118). At week 12, the mean (SD) diurnal IOP was 17.8 (2.9) mmHg with brimonidine-timolol and 17.9 (3.9) mmHg with latanoprost (p = 0.794). The percentage of patients achieving at least a 20% decrease from baseline diurnal IOP at week 12 was 87.7% in the brimonidine-timolol group and 77.3% in the latanoprost group (p = 0.131). Measured biomicroscopic changes from baseline to week 12 were infrequent in both groups. CONCLUSIONS: Fixed-combination brimonidine-timolol was as effective as latanoprost in reducing IOP in patients with glaucoma or ocular hypertension. Both treatments demonstrated favorable ocular tolerability. The duration of the study was 12 weeks, and additional studies will be needed to compare the efficacy and safety of fixed-combination brimonidine-timolol and latanoprost during long-term treatment. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/22458918/Fixed_combination_brimonidine_timolol_versus_latanoprost_in_glaucoma_and_ocular_hypertension:_a_12_week_randomized_comparison_study_ L2 - http://www.tandfonline.com/doi/full/10.1185/03007995.2012.681036 DB - PRIME DP - Unbound Medicine ER -